CasNo.147359-76-0,Flibanserin HCL// Flibanserin Hydrochloride/ BIMT-17 with purity 99%,(147359-76-0) Suppliers

10 Gram	Negotiable

Min.Order :10 Gram
Purity: 99%
Payment Terms : T/T,

Keywords

Flibanserin HCL Flibanserin Hydrochloride BIMT-17

Quick Details

Appearance:white powder
Application:treatment for pre-menopausal women with hypoactive sexual desire disorder
PackAge:discreet packing
ProductionCapacity:500|Kilogram|Month
Storage:cool and dry place
Transportation:EMS,DHL,HK post,EUB,ETK,NL post,Germany post

Superiority:

1.high quality:

quality is life. quality is the most important element for all goods. we have a lab doing research in wuhan china. hplc and nmr is available if needed.

2.reasonable price:

we provide high quality products with competitive price in china. all customers are welcomed to send us inquiries and get quotation.

3.low moq:

no worry about the low moq, our moq is 1 gram or even lower.

4.good service.

fast response. we promise to reply within 24 hours including holidays and send quotation sheet and other documents within 48 hours.

5. fast shipping and secure courier.

we promise to send out products and provide tracking number within 3 working days. and we send via different couriers based on different destination countries. we usually use nl post, hk post, germany post, eub, etk, etc.

Details:

Flibanserin HCL // Flibanserin Hydrochloride /BIMT-17 99.0%min powder

Product Name: Flibanserin Hydrochloride

Chemical Formula: C20H22ClF3N4O

Molecular Weight: 426.86

CAS:147359-76-0

Flibanserin HCL / CAS No.147359-76-0 / Flibanserin Hydrochloride /BIMT-17 99.0%min powder

Character: white powder

Purity (HPLC): 99.0%

Flibanserin Test standard:

Test Items	Test Specifications	Test Results
Appearance	An off-white to white powder	Complied
Identification	Meet the requirements	Positive
Loss on Drying	≤0.50%	0.13%
Heavy Metals	≤20PPM	<20PPM
Purity (by HPLC)	≥99.0%	99.2%
Conclusion:	Conform to standard

Flibanserin HCL (INN, USAN) (developmental code name BIMT-17; proposed trade names Girosa and Addyi) is a drug that is being studied as a non-hormonal treatment for pre-menopausal women with hypoactive sexual desire disorder (HSDD). Development by Boehringer Ingelheim was halted in October 2010 following a negative evaluation by the U.S. Food and Drug Administration. The rights to the drug were then transferred to Sprout Pharmaceuticals, which is continuing the drug development process. On June 4, 2015, the panel to the FDA recommended approval of the drug by 18–6.